Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.48 |
| ▸ | FNTA | P49354 | 7/20 | 0.46 |
| ▸ | FNTB | P49356 | 7/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501971 | 0.88 | SMO (0.39) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL446009 | 0.88 | CYP11B1 (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8009897 | 0.84 | CYP11B1 (0.49) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8151902 | 0.83 | SMO (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL8114048 | 0.82 | FNTA (0.52) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8151756 | 0.81 | CYP11B1 (0.50) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL8107070 | 0.81 | FNTA (0.51) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL448443 | 0.78 | FNTA (0.54) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8657909 | 0.78 | CYP11B1 (0.46) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL28693185 | 0.77 | CYP11B1 (0.52) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096344-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096344-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CYP11B1 3248/4885CYP11B2 3772/4885FNTA 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.